Bioradius Therapeutic Research Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 31.22%
(FY 2023)
- Profit 166.66%
(FY 2023)
- Ebitda 313.82%
(FY 2023)
- Net Worth 31.10%
(FY 2023)
- Total Assets 22.16%
(FY 2023)
About Bioradius Therapeutic Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Senthilmurugan Thyagarajan and Krishnaveni Gadiraju serve as directors at the Company.
- CIN/LLPIN
U74999PN2018PTC175042
- Company No.
175042
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bioradius Therapeutic Research?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Senthilmurugan Thyagarajan  | Additional Director | 18-Mar-2021 | Current |
| Krishnaveni Gadiraju | Additional Director | 18-Mar-2021 | Current |
Financial Performance and Corporate Structure Insights of Bioradius Therapeutic Research.
Bioradius Therapeutic Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.22% increase. The company also saw a substantial improvement in profitability, with a 166.66% increase in profit. The company's net worth Soared by an impressive increase of 31.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioradius Therapeutic Research?
In 2023, Bioradius Therapeutic Research had a promoter holding of 18.60% and a public holding of 81.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Green India Nutraceutical Private LimitedActive 10 years 1 month
Senthilmurugan Thyagarajan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioradius Therapeutic Research?
Bioradius Therapeutic Research has a workforce of 36 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioradius Therapeutic Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioradius Therapeutic Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
